3 terminated, 1 enrolling by invitation, 1 not yet recruiting, 1 recruiting. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 3, Enrolling by invitation 1, Recruiting 1 |
| Phase 1 | 2 | Not yet recruiting 1, Terminated 1 |
Follow RVU120: new trials by email Literature Review of RVU120 trials Research Report on RVU120
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 Medulloblastoma RVU120, Everolimus (Afinitor) tablets - Medulloblastoma Recurrent, Medulloblastoma | Phase 1 | Not yet recruiting | Bożenna Dembowska Bagińska | 48 | 2026-09-01 | 2026-10-08 |
| RVU120 Rollover Study RVU120, Ruxolitinib - Advanced Solid Tumors, Acute Myeloid Leukaemia (AML) | Phase 2 | Enrolling by invitation | Ryvu Therapeutics SA | 14 | 2025-12-04 | 2026-09-17 |
| RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis RVU120, Ruxolitinib - Myelofibrosis | Phase 2 | Terminated | Ryvu Therapeutics SA | 36 | 2024-09-19 | 2026-09-16 |
| Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML RVU120 - Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome | Phase 2 | Terminated | Ryvu Therapeutics SA | 62 | 2024-01-23 | 2026-09-16 |
| Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML RVU120, Venetoclax - Acute Myeloid Leukemia | Phase 2 | Recruiting | Ryvu Therapeutics SA | 98 | 2024-01-05 | 2026-09-18 |
| RVU120 (SEL120) in Patients With Relapse/Refractory Metastatic or Advanced Solid Tumors RVU120 - Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | Ryvu Therapeutics SA | 66 | 2021-08-13 | 2026-09-18 |
Leukemia, Myeloid, Acute (3) · Neoplasm Metastasis (3) · Recurrence (3) · Medulloblastoma (1) · Myelodysplastic Syndromes (1) · Primary Myelofibrosis (1)
Ryvu Therapeutics SA (5) · Bożenna Dembowska Bagińska (1)
Poland (6) · France (3) · Italy (3) · Spain (3)
2025 (1)